Alicia Secor - GW Pharmaceuticals Non-Executive Independent Director

Director

Ms. Alicia Secor is NonExecutive Independent Director of the Company. She is currently President and Chief Executive Officer of Juniper Pharmaceuticals. Ms. Secor brings more than 25 years of leadership experience as a life sciences executive, with a track record in leading businesses and advancing products from clinical development through regulatory approval, commercialization, and global expansion across several therapeutic areas. Ms. Secor was previously Chief Commercial Officer at Zafgen, Inc. and Senior Vice President and Chief Operating Officer at Synageva BioPharma Corporationration Ms. Secor spent 15 years at Genzyme Corporation in diverse leadership roles, most recently as the Global General Manager for the Metabolic Disease Business. During her tenure at Genzyme, Ms. Secor led fully integrated businesses, successfully launching products and achieving sustained revenue growth. Ms. Secor spearheaded several strategic transactions and built high performance teams, resulting in consistent growth and profitability across multiple Genzyme businesses including biomaterials, surgical devices, and injectable therapeutics. Prior to Genzyme, Ms. Secor held positions at Alkermes, Inc. in business development, and at Centocor, Inc. in clinical and commercial operations. She began her career at Pfizer Inc. as a hospitalbased sales representative since 2017.
Age 54
Tenure 7 years
Professional MarksMBA
Phone(44) 1223 235667
Webwww.gwpharm.com
Secor received an M.B.A. from Northeastern University, and a B.S. in Healthcare Administration from the University of New Hampshire and serves as a member of the Board of Directors for the Foundation for PraderWilli Research .

GW Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (3.55) % which means that it has lost $3.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.92) %, meaning that it created substantial loss on money invested by shareholders. GW Pharmaceuticals' management efficiency ratios could be used to measure how well GW Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 43.64 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. GW Pharmaceuticals Plc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist GW Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, GW Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GW Pharmaceuticals Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GWPH to invest in growth at high rates of return. When we think about GW Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Bradley CrewsTitan Machinery
N/A
Kevin LoboParker Hannifin
55
Barry AllenCDW Corp
69
Debra WaltonTradeweb Markets
57
Paula MadoffTradeweb Markets
50
Steven AlesioCDW Corp
64
Virginia AddicottCDW Corp
54
Anton ChristiansonTitan Machinery
64
Scott GanelesTradeweb Markets
54
David NelmsCDW Corp
57
Virginia AlbaneseCDW Corp
51
Donna ZarconeCDW Corp
60
Glenn CreamerCDW Corp
53
Wolfgang SchmittParker Hannifin
72
Theodore CrosbieTitan Machinery
64
Ryan MangoldTradeweb Markets
N/A
Mike HusseyTradeweb Markets
46
Candy ObournParker Hannifin
69
Angela KnightTradeweb Markets
64
Christine HamiltonTitan Machinery
61
Michael DominguezCDW Corp
45
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom. Gw Pharma operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 1161 people. GW Pharmaceuticals Plc (GWPH) is traded on NASDAQ Exchange in USA and employs 1,161 people.

Management Performance

GW Pharmaceuticals Plc Leadership Team

Elected by the shareholders, the GW Pharmaceuticals' board of directors comprises two types of representatives: GW Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GWPH. The board's role is to monitor GW Pharmaceuticals' management team and ensure that shareholders' interests are well served. GW Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GW Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
William Waldegrave, Non-Executive Independent Director
Christopher Tovey, COO, Executive Director
Thomas Lynch, Non-Executive Independent Director
Catherine Mackey, Non-Executive Independent Director
Justin Gover, CEO, Director
Geoffrey Guy, Executive Chairman of the Board
James Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
Julian Gangolli, Executive Director
Alicia Secor, Non-Executive Independent Director
Adam George, CFO, Company Secretary, Director
Cabot Brown, Non-Executive Independent Director
Stephen Wright, Research & Development Director, Executive Director
Darren Cline, Chief Commercial Officer, U.S.

GWPH Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GW Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GW Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GW Pharmaceuticals' short interest history, or implied volatility extrapolated from GW Pharmaceuticals options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Other Consideration for investing in GWPH Stock

If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Content Syndication
Quickly integrate customizable finance content to your own investment portal